CRBU
Caribou Biosciences, Inc. NASDAQ Listed Jul 23, 2021$1.88
After hrs
$1.97
+1.55%
Mkt Cap $182.3M
52w Low $0.73
41.0% of range
52w High $3.54
50d MA $1.96
200d MA $1.94
P/E (TTM)
-1.2x
EV/EBITDA
-1.2x
P/B
1.4x
Debt/Equity
0.2x
ROE
-121.2%
P/FCF
-1.3x
RSI (14)
—
ATR (14)
—
Beta
2.46
50d MA
$1.96
200d MA
$1.94
Avg Volume
1.3M
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
2929 7th Street · Berkeley, CA 94710 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.33 | -0.28 | +15.2% | 1.71 | -2.9% | +6.4% | +15.2% | +18.7% | +15.2% | +10.5% | — |
| Nov 12, 2025 | AMC | -0.36 | -0.30 | +16.7% | 2.26 | +1.8% | -11.9% | -11.9% | -16.4% | -17.3% | -19.5% | — |
| Aug 12, 2025 | AMC | -0.40 | -0.35 | +12.5% | 1.79 | -3.9% | +8.9% | +11.7% | +10.6% | +4.5% | -1.1% | — |
| May 8, 2025 | AMC | -0.43 | -0.43 | +0.0% | 0.79 | +0.0% | -2.0% | +3.6% | -0.9% | +3.7% | +6.3% | — |
| Mar 10, 2025 | AMC | -0.40 | -0.39 | +2.5% | 1.11 | +0.9% | -3.6% | -4.5% | -11.2% | -9.0% | -8.1% | — |
| Nov 6, 2024 | AMC | -0.44 | -0.38 | +13.6% | 2.75 | -3.6% | +1.1% | -2.5% | +1.5% | -14.5% | -20.0% | — |
| Aug 6, 2024 | AMC | -0.45 | -0.42 | +6.7% | 1.96 | +3.6% | -3.1% | +3.1% | -1.0% | -5.6% | -5.1% | — |
| May 7, 2024 | AMC | -0.39 | -0.46 | -17.9% | 3.73 | -2.4% | -6.2% | -2.1% | -5.1% | -0.5% | -2.4% | — |
| Mar 11, 2024 | AMC | -0.22 | -0.39 | -77.3% | 7.22 | -0.8% | -30.5% | -22.4% | -25.8% | -25.6% | -27.6% | — |
| Nov 7, 2023 | AMC | -0.38 | -0.12 | +68.4% | 4.77 | +4.4% | -5.0% | -17.3% | -19.3% | -20.5% | -11.5% | — |
| Aug 8, 2023 | AMC | -0.49 | -0.48 | +2.0% | 6.54 | +2.3% | +5.8% | +10.2% | +6.4% | +2.6% | +0.6% | — |
| May 9, 2023 | AMC | -0.48 | -0.46 | +4.2% | 4.40 | +2.3% | +6.8% | -0.5% | -4.3% | +2.3% | -3.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.95 | $1.94 | -0.5% | -4.6% | +0.0% | +0.5% | -1.0% | +0.0% |
| Mar 9 | Evercore ISI | Maintains | Outperform → Outperform | — | $1.82 | $1.79 | -1.6% | +8.2% | +11.5% | +8.2% | +3.8% | +3.3% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.17 | $2.28 | +5.1% | +0.9% | -1.4% | -3.7% | -4.6% | +3.2% |
| Nov 3 | Citigroup | Maintains | Buy → Buy | — | $2.42 | $3.40 | +40.5% | +0.4% | -10.3% | -9.5% | -11.6% | -13.6% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.77 | $0.77 | -0.5% | -0.3% | +10.1% | +9.9% | +3.6% | +13.7% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.95 | $0.96 | +1.1% | +0.1% | +5.2% | +9.4% | +7.3% | +1.1% |
| Jan 7 | BofA Securities | Maintains | Buy → Buy | — | $1.88 | $1.92 | +2.1% | -0.5% | -8.5% | -12.8% | -17.6% | -17.0% |
| Nov 26 | Citigroup | Maintains | Buy → Buy | — | $2.02 | $2.51 | +24.3% | +0.0% | +8.9% | +8.4% | +17.3% | +7.4% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.09 | $2.12 | +1.4% | -4.8% | -5.3% | -4.8% | -6.2% | -5.3% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.16 | $2.17 | +0.5% | -8.3% | -12.0% | -15.3% | -20.4% | -18.1% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.86 | $1.85 | -0.5% | +2.2% | +11.8% | +12.4% | +17.2% | +14.5% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $1.96 | $2.03 | +3.6% | -3.1% | +3.1% | -1.0% | -5.6% | -5.1% |
| Jul 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.73 | $2.64 | -3.3% | -3.3% | -12.1% | -15.8% | -15.0% | -12.1% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.15 | $2.09 | -2.8% | +0.9% | -1.4% | -2.8% | -9.3% | -12.6% |
| May 16 | Truist | Maintains | Buy → Buy | — | $3.64 | $3.66 | +0.5% | -1.4% | -6.9% | -14.0% | -15.1% | -14.6% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.54 | $3.60 | +1.7% | +4.8% | +2.8% | +2.8% | +1.4% | -4.2% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.23 | $5.39 | +3.1% | +3.1% | +4.8% | +0.4% | +0.0% | +1.1% |
| Mar 12 | RBC Capital | Maintains | Outperform → Outperform | — | $7.22 | $7.16 | -0.8% | -30.5% | -22.4% | -25.8% | -25.6% | -27.6% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.57 | $6.53 | -0.6% | +1.2% | -2.9% | +4.0% | +9.4% | +11.3% |
| Jul 14 | Truist | Maintains | Buy → Buy | — | $8.14 | $6.81 | -16.3% | -22.6% | -22.7% | -15.1% | -17.6% | -18.7% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.40 | $4.50 | +2.3% | +6.8% | -0.5% | -4.3% | +2.3% | -3.4% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.33 | $5.54 | +3.9% | -2.4% | -3.2% | -5.4% | -6.9% | -8.4% |
| Mar 10 | RBC Capital | Maintains | Outperform → Outperform | — | $5.51 | $5.54 | +0.5% | -6.0% | -3.3% | -5.6% | -6.4% | -8.5% |
| Mar 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.51 | $5.54 | +0.5% | -6.0% | -3.3% | -5.6% | -6.4% | -8.5% |
| Aug 29 | Citigroup | Maintains | Buy → Buy | — | $10.23 | $9.94 | -2.8% | -2.6% | -6.8% | -3.5% | +2.8% | -3.8% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.41 | $10.36 | -0.5% | -0.8% | -3.4% | -4.9% | +0.5% | +6.9% |
| Aug 10 | RBC Capital | Maintains | Outperform → Outperform | — | $8.14 | $8.11 | -0.4% | +14.3% | +15.4% | +21.7% | +23.1% | +32.1% |
| May 13 | Citigroup | Maintains | Buy → Buy | — | $8.10 | $8.42 | +4.0% | +10.7% | +20.2% | +19.4% | +12.6% | +6.7% |
| May 12 | SVB Leerink | Maintains | Outperform → Outperform | — | $6.63 | $6.52 | -1.7% | +22.2% | +35.3% | +46.9% | +45.9% | +37.6% |
| May 10 | SVB Leerink | Maintains | Outperform → Outperform | — | $6.67 | $7.00 | +4.9% | +9.3% | -0.6% | +21.4% | +34.5% | +46.0% |
| Mar 22 | SVB Leerink | Maintains | Outperform → Outperform | — | $9.15 | $9.34 | +2.1% | +9.5% | +4.9% | +3.9% | +0.8% | +2.1% |
| Feb 18 | RBC Capital | Maintains | Outperform → Outperform | — | $10.22 | $10.40 | +1.8% | -2.2% | -4.6% | -9.8% | -3.7% | -3.4% |
| Feb 14 | Brookline Capital | Maintains | Buy → Buy | — | $10.71 | $10.80 | +0.8% | +2.8% | +8.2% | +6.2% | -4.6% | -6.6% |
| Dec 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $18.59 | $19.61 | +5.5% | -8.9% | -3.1% | -8.2% | -9.0% | +1.0% |
| Nov 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.05 | $18.05 | +5.9% | +9.0% | -0.7% | +5.6% | +0.1% | -0.8% |
| Nov 15 | Citigroup | Upgrade | Neutral → Buy | — | $21.70 | $22.45 | +3.5% | +0.1% | -0.8% | +2.5% | -4.8% | -1.9% |
| Aug 17 | Citigroup | Maintains | Neutral → Neutral | — | $26.48 | $26.19 | -1.1% | -8.2% | +2.1% | -4.0% | -1.5% | +10.4% |
| Aug 17 | SVB Leerink | Maintains | Outperform → Outperform | — | $26.48 | $26.19 | -1.1% | -8.2% | +2.1% | -4.0% | -1.5% | +10.4% |
| Aug 17 | BofA Securities | Maintains | Buy → Buy | — | $26.48 | $26.19 | -1.1% | -8.2% | +2.1% | -4.0% | -1.5% | +10.4% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
CRBU's 8-K filing appears incomplete, but as a clinical-stage CRISPR biotech company, investors should monitor upcoming announcements for trial results or regulatory milestones that could significantly impact valuations.
Mar 31
8-K
Caribou Biosciences, Inc. -- 8-K Filing
Caribou Biosciences reported 2025 financial results and provided a business update, with the company advancing its CRISPR genome-editing pipeline toward clinical milestones.
Mar 5
Data updated apr 25, 2026 3:04am
· Source: massive.com